VJHemOnc Podcast

In this episode of the VJHemOnc podcast, we are joined by Morie Gertz, MD, MACP, Mayo Clinic, Rochester, MN, a... The post Diagnosing amyloidosis: identifying early signs, appropriate diagnostic tests, and challenges that remain appeared first on VJHemOnc.

VJHemOnc was the official media partner for the recent 2nd International PNH Interest Group (IPIG) Conference held in Paris, France.... The post IPIG 2025 Highlights: challenging situations in PNH, updates from the COMMODORE trials, and more appeared first on VJHemOnc.

In this episode of the VJHemOnc podcast, join us for an insightful conversation with Dr Graham Collins, MA, MBBS, MRCP,... The post Recent advances in Hodgkin lymphoma treatment: novel regimens, ongoing trials & treating R/R disease appeared first on VJHemOnc.

In this episode of the VJHemOnc podcast you will hear from Akshay Sharma, MBBS, MSc, St. Jude Children's Research Hospital,... The post Gene therapy in sickle cell disease: patient selection, potential complications, & more appeared first on VJHemOnc.

Today's VJHemOnc podcast features discussions from the 7th International Workshop on CAR-T and bispecifics (iwCAR-T) 2025, which was held recently... The post Highlights from iwCAR-T 2025: improving the efficacy and safety of CAR T-cells & access in the community appeared first on VJHemOnc.

This episode features leading experts Paolo Ghia, MD, Vita-Salute San Raffaele University, Milan, Italy, and Arnon Kater, MD, PhD, University... The post Updates to the ESMO CLL clinical practice guidelines and implications for relapsed therapy appeared first on VJHemOnc.

VJHemOnc was delighted to be media partners for the 18th International Workshop on Multiple Myeloma (iwMyeloma), held in Miami, FL.... The post Highlights from iwMyeloma 2025: trial updates and practical considerations appeared first on VJHemOnc.

In this VJHemOnc podcast, experts Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, Lydia Scarfò, MD, Vita-Salute San Raffaele University... The post Updates to the ESMO CLL clinical practice guidelines: implications for frontline treatment appeared first on VJHemOnc.

In this week's VJHemOnc podcast, we'll be sharing highlights from the 51st Annual Meeting of the EBMT, with a focus... The post Highlights from EBMT 2025: preventing and managing GvHD, harnessing AI in transplant, & more appeared first on VJHemOnc.

This podcast episode features experts Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Gloria Iacoboni,... The post Sequencing therapies in R/R NHL: immunotherapy in DLBCL, BTKis in MCL, & more! appeared first on VJHemOnc.

CAR T-cell therapy has revolutionized the lymphoma treatment landscape in recent years. In this episode, we delve into cutting-edge CAR... The post Novel CAR strategies being explored in lymphoma: allogeneic products, trispecific CARs & new manufacturing platforms appeared first on VJHemOnc.

Newly diagnosed acute myeloid leukemia (AML) is traditionally treated with intensive chemotherapy for eligible patients, but ongoing research is exploring... The post Approaches to optimizing induction therapy in AML: FLT3 inhibitors, menin inhibitors, CPX-351, & more! appeared first on VJHemOnc.

BTK inhibitors have transformed the treatment landscape in both frontline and relapsed/refractory (R/R) mantle cell lymphoma (MCL), offering a targeted... The post Treating R/R mantle cell lymphoma: the role of BTK inhibitors, combination approaches being explored & overcoming resistance appeared first on VJHemOnc.

In recognition of Myeloma Awareness Month 2025, this podcast explores key unmet needs and unanswered questions in myeloma research and... The post Addressing unmet needs in myeloma: early detection, frail/elderly patients, triple-class exposed disease, & more! appeared first on VJHemOnc.

CAR T-cell therapy has become an established treatment for several hematological malignancies, including acute lymphoblastic leukemia (ALL), and has significantly... The post CAR T-cell therapy in ALL: trial updates, novel approaches, & real-world outcomes appeared first on VJHemOnc.

Today's podcast features a discussion with experts Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, and Ashutosh Wechalekar,... The post Post-ASH amyloidosis highlights: the ANDROMEDA trial, risk stratification, value of MRD, & more! appeared first on VJHemOnc.

This episode of the VJHemOnc podcast covers updates in non-malignant hematological diseases from the 66th American Society of Hematology (ASH)... The post Post-ASH non-malignant highlights: updates in sickle cell disease, thalassemia, and hemophilia appeared first on VJHemOnc.

This podcast brings you exclusive updates on multiple myeloma from the 66th American Society of Hematology (ASH) Annual Meeting and... The post Post-ASH myeloma highlights: key takeaways for community physicians & trials to look out for in 2025 appeared first on VJHemOnc.

In this podcast, we bring you exclusive updates in acute myeloid leukemia (AML) from the 66th American Society of Hematology... The post Post-ASH AML highlights: novel approaches to frontline therapy, advances with menin inhibitors, & managing FLT3-ITD+ AML appeared first on VJHemOnc.

This podcast episode covers highlights in myeloproliferative neoplasms (MPNs) from the 66th American Society of Hematology (ASH) Annual Meeting and... The post Post-ASH MPN highlights: key trial updates in MF, novel approaches being explored in R/R disease, & more! appeared first on VJHemOnc.

Today's podcast showcases key updates in non-Hodgkin lymphoma (NHL) from the 66th American Society of Hematology (ASH) Annual Meeting and... The post Post-ASH NHL highlights: novel combinations in the frontline setting and advancements with immunotherapy in the R/R setting appeared first on VJHemOnc.

This podcast is the second episode in our series spotlighting key highlights from the 66th American Society of Hematology (ASH)... The post Post-ASH MDS highlights: managing anemia in LR-MDS and novel approaches to treating HR-MDS appeared first on VJHemOnc.

VJHemOnc recently attended the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA, where we... The post Post-ASH CLL highlights: BTK inhibitors & degraders, bispecific antibodies, & more! appeared first on VJHemOnc.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by involvement of the skin, bone... The post Advancing treatment for BPDCN: current therapies, a deep dive into tagraxofusp, & emerging novel agents appeared first on VJHemOnc.

This week's podcast focuses on strategies to improve care for patients with sickle cell disease (SCD), featuring expert insights from... The post Improving care for patients with SCD: pain management, ongoing projects & unmet needs appeared first on VJHemOnc.

In this podcast, experts Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, Nicole LeBoeuf, MD, MPH, Dana-Farber Cancer Institute,... The post Understanding BPDCN: dermatology and hematology perspectives on presentation, diagnosis, treatment, & multidisciplinary care appeared first on VJHemOnc.

Today's podcast episode focuses on the management of complications associated with Waldenström's macroglobulinemia (WM), featuring expert insights from the 12th... The post Managing complications associated with WM: Bing-Neel syndrome, acquired von Willebrand disease, & more! appeared first on VJHemOnc.

This week's podcast features discussions on the use of immunotherapy in the treatment of high-risk multiple myeloma (HRMM) from the... The post CAR-T therapies and bispecific antibodies in the treatment of high-risk multiple myeloma: updates from iwHRMM 2024 appeared first on VJHemOnc.

This podcast features a discussion from the 6th International Workshop on Acute Leukemias (iwAL) 2024, which took place in Phoenix,... The post The treatment landscape and challenges in rare diseases: BPDCN, CMML, MPN-AP/BP, and VEXAS appeared first on VJHemOnc.

Today's podcast focuses on the role of BTK inhibitors (BTKis) in the treatment of mantle cell lymphoma (MCL). You will... The post Exploring the role of BTK inhibitors in mantle cell lymphoma: sequencing & managing adverse events appeared first on VJHemOnc.

Menin inhibitors are emerging as a promising therapeutic approach in acute myeloid leukemia (AML), particularly in patients with specific genetic... The post An update on menin inhibition in AML from iwAL 2024: current data, mechanisms of resistance, & more! appeared first on VJHemOnc.

Today's podcast features discussions from the 21st International Workshop on Non-Hodgkin Lymphoma (iwNHL) which took place in Nice, France. You... The post CAR T-cells and bispecific antibodies in the treatment of NHL: updates from iwNHL 2024 appeared first on VJHemOnc.

Today's podcast features a discussion with leading experts Harry Erba, MD, PhD, Duke University, Durham, NC, Farhad Ravandi, MD, The... The post Prolonging remission in AML: current approaches & future outlooks appeared first on VJHemOnc.

Welcome to the final episode of VJHemOnc's Blood Cancer Awareness Month special series! This episode focuses on the role of... The post A focus on the use of artificial intelligence to personalize blood cancer care appeared first on VJHemOnc.

Welcome to the third episode of VJHemOnc's Blood Cancer Awareness Month special series!  The focus of this episode is pediatric... The post A focus on pediatric leukemias: trials, treatments, & challenges appeared first on VJHemOnc.

Welcome to the second episode of VJHemOnc's Blood Cancer Awareness Month special series!  Today's episode focuses on the psychosocial impacts... The post A focus on the psychosocial impacts of living with blood cancer appeared first on VJHemOnc.

Welcome to the first episode of VJHemOnc's Blood Cancer Awareness Month special series!  This episode focuses on global perspectives of... The post Global perspectives on blood cancers: addressing disparities in awareness, diagnosis, and treatment appeared first on VJHemOnc.

Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPNs) characterized by the overproduction of red blood cells and... The post Insights into PV and ET: treating the AYA population, defining goals when treating patients, & more appeared first on VJHemOnc.

This week's VJHemOnc podcast brings you updates in hemophilia from the 32nd Congress of the International Society on Thrombosis and... The post Hemophilia updates from ISTH 2024: ongoing clinical trials, emerging gene therapies & remaining challenges appeared first on VJHemOnc.

In myelodysplastic syndromes (MDS), chronic inflammation driven by the innate immune system plays a key role in disease progression. Signal... The post Inflammation and immune interventions in MDS: targeting STAT, IRAK4, & more appeared first on VJHemOnc.

Today's VJHemOnc podcast features experts Rabi Hanna, MD, The Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, Subarna Chakravorty, MBBS, MRCPCH,... The post Updates in the treatment of SCD and thalassemia from EHA 2024: key trial updates, challenges with gene therapies & unmet needs appeared first on VJHemOnc.

Myelofibrosis (MF) is a chronic myeloproliferative neoplasm (MPN) characterized by bone marrow fibrosis, extramedullary hematopoiesis, and splenomegaly, often resulting in... The post Unmet treatment needs in MF: managing prefibrotic disease & thrombocytopenia, novel agents & endpoints for clinical trials appeared first on VJHemOnc.

The introduction of Bruton's tyrosine kinase (BTK) inhibitors into the treatment landscape for mantle cell lymphoma (MCL) has transformed the... The post The role of BTK inhibitors in MCL, ongoing trials & future outlooks: updates from EHA 2024 appeared first on VJHemOnc.

In today's VJHemOnc podcast, we will be sharing novel developments in lower-risk myelodysplastic syndromes (LR-MDS) and important practical considerations when treating patients.... The post Novel developments in lower-risk MDS & important practical considerations when treating patients appeared first on VJHemOnc.

BCMA-targeting bispecific antibodies treat multiple myeloma by binding to BCMA on malignant plasma cells and directing T-cells to initiate targeted... The post Updates on the use of BCMA-targeting bispecific antibodies in R/R multiple myeloma: insights from EHA & ASCO 2024 appeared first on VJHemOnc.

In today's VJHemOnc podcast, we will be sharing key updates in the treatment of chronic lymphocytic leukemia (CLL) and Richter's... The post Updates in the treatment of CLL from EHA 2024: BTK and BCL2 inhibitor combinations, BTK degraders, and more appeared first on VJHemOnc.

Welcome to today's VJHemOnc podcast episode, where we will be sharing key highlights from the 2024 International Symposium on Amyloidosis... The post Highlights from ISA 2024: the importance of early diagnosis in AL amyloidosis, trials in progress & patient selection for SCT appeared first on VJHemOnc.

While there have been advances in the treatment of lower-risk myelodysplastic syndromes (LR-MDS) in recent years, one major challenge that... The post Treating LR-MDS beyond ESA failure: currently approved agents, novel approaches & future outlooks appeared first on VJHemOnc.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy originating from plasmacytoid dendritic cells, characterized by skin lesions... The post BPDCN treatment and management: CD123-targeting agents, CNS involvement & approaching pediatric/AYA patients appeared first on VJHemOnc.

Immunotherapeutic approaches, including CAR T-cells and bispecific antibodies, have become well-established in later lines of non-Hodgkin lymphoma (NHL) treatment. CAR... The post The future of CAR-T therapy in lymphoma, addressing the risk of secondary malignancy & the optimal sequencing of these agents with bispecific antibodies appeared first on VJHemOnc.

The 17th International Workshop on Multiple Myeloma (iwMyeloma 2024) was held recently in Miami, FL, and brought together experts from... The post iwMyeloma 2024 Session I: approaching bone disease, clinical trial updates & the value of MRD as an endpoint in trials appeared first on VJHemOnc.